Clinical Trial Update: RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update of RNA-immunotherapy IVAC_W_bre1_uID and IVAC_M_uID in triple-negative breast cancer, with the study status now completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• IVAC_M_uID
• IVAC_W_bre1_uID

Snippet

Sponsor: BioNTech SE | Conditions: Breast Cancer (Triple Negative Breast Cancer (TNBC)) | Phase 1 | Status: COMPLETED